Related Experiment Videos
The renal monoamine oxidases: pathophysiology and targets for therapeutic intervention
N Pizzinat1, A Remaury, A Parini
1INSERM U388, Department of Renal Molecular Pharmacology and Physiology, University Hospital Centre, Rangueil, Toulouse, France.
Current Opinion in Nephrology and Hypertension
|January 27, 1998
Abstract:
The mitochondrial enzyme monoamine oxidases A and B are among the major metabolic agents for the degradation of the biogenic amines adrenaline, noradrenaline, dopamine and serotonin. The fact that the kidney contains a large amount of monoamine oxidase suggests that the renal effects of biogenic amines might depend in part on the activity of these enzymes.